What are the most common mistakes with Teriparatide?
The most common Teriparatide mistakes are continuing past ~2 years without an ongoing high-fracture-risk reason (the hard lifetime cap was removed in 2020); skipping calcium / vitamin D adequacy first; underestimating the prescription-and-monitoring requirement. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Teriparatide is limited.
Common Teriparatide mistakes
- Continuing past ~2 years without an ongoing high-fracture-risk reason (the hard lifetime cap was removed in 2020)
- Skipping calcium / vitamin D adequacy first
- Underestimating the prescription-and-monitoring requirement
Bloodwork worth tracking
- Serum calcium baseline + at 1 month + every 6 months
- 25-OH vitamin D
References
- Effect of Teriparatide on the risk of fractures in postmenopausal women with osteoporosis — Neer RM et al., NEJM, 2001
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial — Kendler DL, Marin F, Geusens P, et al. — The Lancet, 2018
- FORTEO (teriparatide) injection — FDA Prescribing Information — FDA / DailyMed (Eli Lilly and Company)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Teriparatide
Last updated 2026-06-15.